IR & PR Clients

See why more than 250 companies chose WWFinancial to increase awareness, coverage and relevance.

CEO, Usio, Inc.

Louis Hoch

usio.com

“Having worked with WWFinancial in the past, I had no hesitation in again engaging the firm when Usio, Inc. needed to institute an investor relations program. As I had expected, …

READ FULL STORY

CEO, Sonoma Pharmaceuticals

Jim Schutz

sonomapharma.com

“For small and micro-cap companies like Sonoma Pharmaceuticals, it doesn’t make any sense to have an in-house investor relations professional when there is a firm like WWFinancial that can provide …

READ FULL STORY

Former CEO, IsoRay

Dwight Babcock

isoray.com

“We had a terrific, productive relationship with WWFinancial, at a pivotal point in IsoRay’s development. The WWFinancial was highly engaged with us, personalizing their efforts to seamlessly match our philosophies …

READ FULL STORY

usio.com

NASDAQ

PYDS

INDUSTRY

Financial

TYPE

B2C, B2B

Usio, Inc.

Usio, Inc. is an integrated payment solutions provider to merchants and billers. The organization provides an extensive set of products to deliver world-class payment acceptance. Usio has solutions for merchants, …

WWFinancial Provided

Implemented a comprehensive Financial PR program at the same time as the company uplisting to the NASDAQ market.

Result

After the first half of our program launch, the 20d average volume gradually increased from 4,000 shares to over 300,000 shares.

gromsocial.com

OTC

GRMM

INDUSTRY

Entertainment

TYPE

B2C

Grom Social, Inc.

Grom Social Enterprises, Inc., through its subsidiaries, operates social media network designed for children in the United States. It is also involved in the animation business; and provision of WebFiltering …

WWFinancial Provided

Financial PR and investor engagement.

Result

Increased retail brokerage sponsorship and investor awareness.

actiniumpharma.com

NYSE

ATNM

INDUSTRY

Biotech

TYPE

B2C

Actinium Pharmaceuticals, Inc.

Actinium is developing two radioimmunotherapy (RIT) drugs based on its APIT drug delivery platform. Iomab-B is being developed for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT) in relapsed …

WWFinancial Provided

PROVIDED

Result

Text result

ibioinc.com

NYSE

IBIO

INDUSTRY

Pharmaceutical

TYPE

B2C

iBio, Inc.

iBio, Inc. develops pharmaceutical product applications using its iBio Technology platform; a platform that has proven to be more efficient and cost-effective than traditional systems. The iBioLaunch platform is a …

WWFinancial Provided

We applied strategic marketing techniques toward enhancing interest in the institutional and analysts community.

Result

Increased the 20d average volume from 50K shares a day to over 120K.

sonomapharma.com

NASDAQ

SNOA

INDUSTRY

Pharmaceutical

TYPE

B2C

Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are …

WWFinancial Provided

Engaged proactive marketing program to generate retail brokerage sponsorship.

Result

Institutional holdings increased 20% within first 6 months of program.

IR & PR Clients

Louis Hoch

Jim Schutz

Dwight Babcock

Usio, Inc.

WWFinancial Provided

Result

Grom Social, Inc.

WWFinancial Provided

Result

Actinium Pharmaceuticals, Inc.

WWFinancial Provided

Result

iBio, Inc.

WWFinancial Provided

Result

Sonoma Pharmaceuticals, Inc.

WWFinancial Provided

Result

We help you market your investment story with maximum impact and deliver your corporate message effectively